New Delhi, Jul 15: Drug firm Zydus Cadila on Wednesday said it has started human clinical trials of its COVID-19 vaccine candidate ZyCoV-D. In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing.

Also Read | WBBSE Madhyamik Result 2020 Live News Updates: West Bengal Class 10 Board Exam Result Declared, Alternative Website to Check Marks Online.

The adaptive phase I/ II human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that “the adaptive phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine.” First COVID-19 Vaccine Tested in US Shows Promising Immune Response Ahead of Final Testing.

Earlier this month, Zydus had received approval from domestic authorities to start human trials for its COVID-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide.

Also Read | Identical Twin Sisters in Noida, Mansi and Manya, Score Identical Marks in CBSE 12th Board Exams 2020, Secure 95.8%.

It got approval a few days after India's first indigenous COVID-19 vaccine candidate COVAXIN, developed by city-based Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, got the nod for human clinical trials from the Drug Controller General of India

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 356.50 apiece on BSE, up 0.81 per cent against their previous close.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)